The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Prevalence of MASLD
Timeframe: 2031
Progression/regression of MASLD
Timeframe: 2031
Predictors of MASLD progression/regression
Timeframe: 2031
Prevalence of advanced fibrosis
Timeframe: 2031
Progression/regression of advanced fibrosis
Timeframe: 2031
Predictors of fibrosis progression/regression
Timeframe: 2031
The association between physical activity and prevalent advanced fibrosis
Timeframe: 2031
The association between physical activity and risk of progressing to advanced fibrosis
Timeframe: 2031
Genetic factors associated with advanced fibrosis or MASLD progression/regression
Timeframe: 2031
Association between body composition and MASLD and/or liver fibrosis and progression/regression thereof
Timeframe: 2031